APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Hemoglobinopathy Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Hemoglobinopathy Treatment Market Analysis and Forecast 2026-2032

Report ID 173997500220 December 2025194 pages

Choose your research edition.

Industry ResearchHemoglobinopathy Treatment Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemoglobinopathy Treatment Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Hemoglobinopathy Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemoglobinopathy Treatment Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemoglobinopathy Treatment Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Hemoglobinopathy Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Hemoglobinopathy Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Hemoglobinopathy Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Hemoglobinopathy Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Hemoglobinopathy Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Hemoglobinopathy Treatment include Novartis, Eli Lilly and Company, AstraZeneca, HemaQuest Pharmaceuticals, Emmaus Medical, Celgene, Bristol-Myers Squibb, Bluebird and Acceleron Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Hemoglobinopathy Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hemoglobinopathy Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Hemoglobinopathy Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hemoglobinopathy Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hemoglobinopathy Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Hemoglobinopathy Treatment revenue, projected growth trends, production technology, application and end-user industry.

Hemoglobinopathy Treatment Segment by Company

Novartis

Eli Lilly and Company

AstraZeneca

HemaQuest Pharmaceuticals

Emmaus Medical

Celgene

Bristol-Myers Squibb

Bluebird

Acceleron Pharma

Hemoglobinopathy Treatment Segment by Type

Hydroxyurea

Glutamine

Zynteglo

Other

Hemoglobinopathy Treatment Segment by Application

Sickle Cell Diseases

Thalassemia

Hemoglobinopathy Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemoglobinopathy Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemoglobinopathy Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemoglobinopathy Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Hemoglobinopathy Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Hemoglobinopathy Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hemoglobinopathy Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hemoglobinopathy Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Hydroxyurea Major Player Table 3. Glutamine Major Player Table 4. Zynteglo Major Player Table 5. Other Major Player Table 6. Global Hemoglobinopathy Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Sickle Cell Diseases Major Player Table 8. Thalassemia Major Player Table 9. Hemoglobinopathy Treatment Industry Trends Table 10. Hemoglobinopathy Treatment Industry Drivers Table 11. Hemoglobinopathy Treatment Industry Opportunities and Challenges Table 12. Hemoglobinopathy Treatment Industry Restraints Table 13. Global Hemoglobinopathy Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Hemoglobinopathy Treatment Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Hemoglobinopathy Treatment Market Share by Region (2021-2026) Table 16. Global Hemoglobinopathy Treatment Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Hemoglobinopathy Treatment Market Share by Region (2027-2032) Table 18. Global Hemoglobinopathy Treatment Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Hemoglobinopathy Treatment Revenue Market Share by Players (2021-2026) Table 20. Global Hemoglobinopathy Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Hemoglobinopathy Treatment Key Players Headquarters & Area Served Table 22. Global Hemoglobinopathy Treatment Players, Product Type & Application Table 23. Global Hemoglobinopathy Treatment Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Hemoglobinopathy Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Hemoglobinopathy Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Hemoglobinopathy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Hemoglobinopathy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Hemoglobinopathy Treatment Revenue Market Share by Type (2021-2026) Table 30. Global Hemoglobinopathy Treatment Revenue Market Share by Type (2027-2032) Table 31. Global Hemoglobinopathy Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Hemoglobinopathy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Hemoglobinopathy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Hemoglobinopathy Treatment Revenue Market Share by Application (2021-2026) Table 35. Global Hemoglobinopathy Treatment Revenue Market Share by Application (2027-2032) Table 36. Novartis Company Information Table 37. Novartis Business Overview Table 38. Novartis Hemoglobinopathy Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Novartis Hemoglobinopathy Treatment Product Portfolio Table 40. Novartis Recent Development Table 41. Eli Lilly and Company Company Information Table 42. Eli Lilly and Company Business Overview Table 43. Eli Lilly and Company Hemoglobinopathy Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Eli Lilly and Company Hemoglobinopathy Treatment Product Portfolio Table 45. Eli Lilly and Company Recent Development Table 46. AstraZeneca Company Information Table 47. AstraZeneca Business Overview Table 48. AstraZeneca Hemoglobinopathy Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. AstraZeneca Hemoglobinopathy Treatment Product Portfolio Table 50. AstraZeneca Recent Development Table 51. HemaQuest Pharmaceuticals Company Information Table 52. HemaQuest Pharmaceuticals Business Overview Table 53. HemaQuest Pharmaceuticals Hemoglobinopathy Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. HemaQuest Pharmaceuticals Hemoglobinopathy Treatment Product Portfolio Table 55. HemaQuest Pharmaceuticals Recent Development Table 56. Emmaus Medical Company Information Table 57. Emmaus Medical Business Overview Table 58. Emmaus Medical Hemoglobinopathy Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Emmaus Medical Hemoglobinopathy Treatment Product Portfolio Table 60. Emmaus Medical Recent Development Table 61. Celgene Company Information Table 62. Celgene Business Overview Table 63. Celgene Hemoglobinopathy Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Celgene Hemoglobinopathy Treatment Product Portfolio Table 65. Celgene Recent Development Table 66. Bristol-Myers Squibb Company Information Table 67. Bristol-Myers Squibb Business Overview Table 68. Bristol-Myers Squibb Hemoglobinopathy Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Bristol-Myers Squibb Hemoglobinopathy Treatment Product Portfolio Table 70. Bristol-Myers Squibb Recent Development Table 71. Bluebird Company Information Table 72. Bluebird Business Overview Table 73. Bluebird Hemoglobinopathy Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Bluebird Hemoglobinopathy Treatment Product Portfolio Table 75. Bluebird Recent Development Table 76. Acceleron Pharma Company Information Table 77. Acceleron Pharma Business Overview Table 78. Acceleron Pharma Hemoglobinopathy Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Acceleron Pharma Hemoglobinopathy Treatment Product Portfolio Table 80. Acceleron Pharma Recent Development Table 81. North America Hemoglobinopathy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 82. North America Hemoglobinopathy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 83. North America Hemoglobinopathy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 84. North America Hemoglobinopathy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 85. North America Hemoglobinopathy Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 86. North America Hemoglobinopathy Treatment Revenue by Country (2021-2026) & (US$ Million) Table 87. North America Hemoglobinopathy Treatment Revenue by Country (US$ Million) & (2027-2032) Table 88. Europe Hemoglobinopathy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 89. Europe Hemoglobinopathy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 90. Europe Hemoglobinopathy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 91. Europe Hemoglobinopathy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 92. Europe Hemoglobinopathy Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 93. Europe Hemoglobinopathy Treatment Revenue by Country (2021-2026) & (US$ Million) Table 94. Europe Hemoglobinopathy Treatment Revenue by Country (US$ Million) & (2027-2032) Table 95. China Hemoglobinopathy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 96. China Hemoglobinopathy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 97. China Hemoglobinopathy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 98. China Hemoglobinopathy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 99. Asia Hemoglobinopathy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 100. Asia Hemoglobinopathy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 101. Asia Hemoglobinopathy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 102. Asia Hemoglobinopathy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 103. Asia Hemoglobinopathy Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 104. Asia Hemoglobinopathy Treatment Revenue by Region (US$ Million) & (2021-2026) Table 105. Asia Hemoglobinopathy Treatment Revenue by Region (US$ Million) & (2027-2032) Table 106. SAMEA Hemoglobinopathy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 107. SAMEA Hemoglobinopathy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 108. SAMEA Hemoglobinopathy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 109. SAMEA Hemoglobinopathy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 110. SAMEA Hemoglobinopathy Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. SAMEA Hemoglobinopathy Treatment Revenue by Country (2021-2026) & (US$ Million) Table 112. SAMEA Hemoglobinopathy Treatment Revenue by Country (US$ Million) & (2027-2032) Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Hemoglobinopathy Treatment Image Figure 2. Global Hemoglobinopathy Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hemoglobinopathy Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Hydroxyurea Image Figure 5. Glutamine Image Figure 6. Zynteglo Image Figure 7. Other Image Figure 8. Global Hemoglobinopathy Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Hemoglobinopathy Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 10. Sickle Cell Diseases Image Figure 11. Thalassemia Image Figure 12. Global Hemoglobinopathy Treatment Market Size (US$ Million) & (2021-2032) Figure 13. Global Hemoglobinopathy Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Hemoglobinopathy Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Hemoglobinopathy Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Hemoglobinopathy Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Hemoglobinopathy Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Hemoglobinopathy Treatment Revenue Market Share by Type (2021-2032) Figure 20. Global Hemoglobinopathy Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Hemoglobinopathy Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Hemoglobinopathy Treatment Revenue Market Share by Application (2021-2032) Figure 23. North America Hemoglobinopathy Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Hemoglobinopathy Treatment Revenue Share by Type (2021-2032) Figure 25. North America Hemoglobinopathy Treatment Revenue Share by Application (2021-2032) Figure 26. North America Hemoglobinopathy Treatment Revenue Share by Country (2021-2032) Figure 27. United States Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Hemoglobinopathy Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Hemoglobinopathy Treatment Revenue Share by Type (2021-2032) Figure 32. Europe Hemoglobinopathy Treatment Revenue Share by Application (2021-2032) Figure 33. Europe Hemoglobinopathy Treatment Revenue Share by Country (2021-2032) Figure 34. Germany Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Hemoglobinopathy Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Hemoglobinopathy Treatment Revenue Share by Type (2021-2032) Figure 44. China Hemoglobinopathy Treatment Revenue Share by Application (2021-2032) Figure 45. Asia Hemoglobinopathy Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Hemoglobinopathy Treatment Revenue Share by Type (2021-2032) Figure 47. Asia Hemoglobinopathy Treatment Revenue Share by Application (2021-2032) Figure 48. Asia Hemoglobinopathy Treatment Revenue Share by Region (2021-2032) Figure 49. Japan Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Hemoglobinopathy Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Hemoglobinopathy Treatment Revenue Share by Type (2021-2032) Figure 57. SAMEA Hemoglobinopathy Treatment Revenue Share by Application (2021-2032) Figure 58. SAMEA Hemoglobinopathy Treatment Revenue Share by Country (2021-2032) Figure 59. Brazil Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Hemoglobinopathy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Hydroxyurea
  • Glutamine
  • Zynteglo
  • Other
Applications
  • Sickle Cell Diseases
  • Thalassemia
Companies covered
  • Novartis
  • Eli Lilly and Company
  • AstraZeneca
  • HemaQuest Pharmaceuticals
  • Emmaus Medical
  • Celgene
  • Bristol-Myers Squibb
  • Bluebird
  • Acceleron Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hemoglobinopathy Treatment Market by Type
  3. 1.2.1 Global Hemoglobinopathy Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Hydroxyurea
  5. 1.2.3 Glutamine
  6. 1.2.4 Zynteglo
  7. 1.2.5 Other
  8. 1.3 Hemoglobinopathy Treatment Market by Application
  9. 1.3.1 Global Hemoglobinopathy Treatment Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Sickle Cell Diseases
  11. 1.3.3 Thalassemia
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Hemoglobinopathy Treatment Market Dynamics
  1. 2.1 Hemoglobinopathy Treatment Industry Trends
  2. 2.2 Hemoglobinopathy Treatment Industry Drivers
  3. 2.3 Hemoglobinopathy Treatment Industry Opportunities and Challenges
  4. 2.4 Hemoglobinopathy Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Hemoglobinopathy Treatment Market Perspective (2021-2032)
  2. 3.2 Global Hemoglobinopathy Treatment Growth Trends by Region
  3. 3.2.1 Global Hemoglobinopathy Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hemoglobinopathy Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Hemoglobinopathy Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Hemoglobinopathy Treatment Revenue by Players
  2. 4.1.1 Global Hemoglobinopathy Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Hemoglobinopathy Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Hemoglobinopathy Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hemoglobinopathy Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Hemoglobinopathy Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Hemoglobinopathy Treatment Players, Product Type & Application
  8. 4.5 Global Hemoglobinopathy Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Hemoglobinopathy Treatment Market CR5 and HHI
  11. 4.6.3 2025 Hemoglobinopathy Treatment Tier 1, Tier 2, and Tier 3
5 Hemoglobinopathy Treatment Market Size by Type
  1. 5.1 Global Hemoglobinopathy Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Hemoglobinopathy Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Hemoglobinopathy Treatment Revenue Market Share by Type (2021-2032)
6 Hemoglobinopathy Treatment Market Size by Application
  1. 6.1 Global Hemoglobinopathy Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Hemoglobinopathy Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Hemoglobinopathy Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Hemoglobinopathy Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Hemoglobinopathy Treatment Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Eli Lilly and Company
  8. 7.2.1 Eli Lilly and Company Company Information
  9. 7.2.2 Eli Lilly and Company Business Overview
  10. 7.2.3 Eli Lilly and Company Hemoglobinopathy Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eli Lilly and Company Hemoglobinopathy Treatment Product Portfolio
  12. 7.2.5 Eli Lilly and Company Recent Developments
  13. 7.3 AstraZeneca
  14. 7.3.1 AstraZeneca Company Information
  15. 7.3.2 AstraZeneca Business Overview
  16. 7.3.3 AstraZeneca Hemoglobinopathy Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 AstraZeneca Hemoglobinopathy Treatment Product Portfolio
  18. 7.3.5 AstraZeneca Recent Developments
  19. 7.4 HemaQuest Pharmaceuticals
  20. 7.4.1 HemaQuest Pharmaceuticals Company Information
  21. 7.4.2 HemaQuest Pharmaceuticals Business Overview
  22. 7.4.3 HemaQuest Pharmaceuticals Hemoglobinopathy Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 HemaQuest Pharmaceuticals Hemoglobinopathy Treatment Product Portfolio
  24. 7.4.5 HemaQuest Pharmaceuticals Recent Developments
  25. 7.5 Emmaus Medical
  26. 7.5.1 Emmaus Medical Company Information
  27. 7.5.2 Emmaus Medical Business Overview
  28. 7.5.3 Emmaus Medical Hemoglobinopathy Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Emmaus Medical Hemoglobinopathy Treatment Product Portfolio
  30. 7.5.5 Emmaus Medical Recent Developments
  31. 7.6 Celgene
  32. 7.6.1 Celgene Company Information
  33. 7.6.2 Celgene Business Overview
  34. 7.6.3 Celgene Hemoglobinopathy Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Celgene Hemoglobinopathy Treatment Product Portfolio
  36. 7.6.5 Celgene Recent Developments
  37. 7.7 Bristol-Myers Squibb
  38. 7.7.1 Bristol-Myers Squibb Company Information
  39. 7.7.2 Bristol-Myers Squibb Business Overview
  40. 7.7.3 Bristol-Myers Squibb Hemoglobinopathy Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Bristol-Myers Squibb Hemoglobinopathy Treatment Product Portfolio
  42. 7.7.5 Bristol-Myers Squibb Recent Developments
  43. 7.8 Bluebird
  44. 7.8.1 Bluebird Company Information
  45. 7.8.2 Bluebird Business Overview
  46. 7.8.3 Bluebird Hemoglobinopathy Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Bluebird Hemoglobinopathy Treatment Product Portfolio
  48. 7.8.5 Bluebird Recent Developments
  49. 7.9 Acceleron Pharma
  50. 7.9.1 Acceleron Pharma Company Information
  51. 7.9.2 Acceleron Pharma Business Overview
  52. 7.9.3 Acceleron Pharma Hemoglobinopathy Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Acceleron Pharma Hemoglobinopathy Treatment Product Portfolio
  54. 7.9.5 Acceleron Pharma Recent Developments
8 North America
  1. 8.1 North America Hemoglobinopathy Treatment Revenue (2021-2032)
  2. 8.2 North America Hemoglobinopathy Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Hemoglobinopathy Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Hemoglobinopathy Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Hemoglobinopathy Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Hemoglobinopathy Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Hemoglobinopathy Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Hemoglobinopathy Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Hemoglobinopathy Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Hemoglobinopathy Treatment Revenue by Country
  11. 8.6.1 North America Hemoglobinopathy Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Hemoglobinopathy Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Hemoglobinopathy Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Hemoglobinopathy Treatment Revenue (2021-2032)
  2. 9.2 Europe Hemoglobinopathy Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Hemoglobinopathy Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Hemoglobinopathy Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Hemoglobinopathy Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Hemoglobinopathy Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Hemoglobinopathy Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Hemoglobinopathy Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Hemoglobinopathy Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Hemoglobinopathy Treatment Revenue by Country
  11. 9.6.1 Europe Hemoglobinopathy Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Hemoglobinopathy Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Hemoglobinopathy Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Hemoglobinopathy Treatment Revenue (2021-2032)
  2. 10.2 China Hemoglobinopathy Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Hemoglobinopathy Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Hemoglobinopathy Treatment Revenue by Type (2027-2032)
  5. 10.3 China Hemoglobinopathy Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Hemoglobinopathy Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Hemoglobinopathy Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Hemoglobinopathy Treatment Revenue by Application (2027-2032)
  9. 10.5 China Hemoglobinopathy Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hemoglobinopathy Treatment Revenue (2021-2032)
  2. 11.2 Asia Hemoglobinopathy Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Hemoglobinopathy Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Hemoglobinopathy Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Hemoglobinopathy Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Hemoglobinopathy Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Hemoglobinopathy Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Hemoglobinopathy Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Hemoglobinopathy Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Hemoglobinopathy Treatment Revenue by Country
  11. 11.6.1 Asia Hemoglobinopathy Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Hemoglobinopathy Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Hemoglobinopathy Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hemoglobinopathy Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Hemoglobinopathy Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Hemoglobinopathy Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Hemoglobinopathy Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Hemoglobinopathy Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Hemoglobinopathy Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Hemoglobinopathy Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Hemoglobinopathy Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Hemoglobinopathy Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Hemoglobinopathy Treatment Revenue by Country
  11. 12.6.1 SAMEA Hemoglobinopathy Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Hemoglobinopathy Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Hemoglobinopathy Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst